

K111999

APR 17 2012

510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Submitted By: HEALGEN SCIENTIFIC LLC
5213 Maple Street, Bellaire, TX77401

Official Correspondent:

Yongquan Wang
HEALGEN SCIENTIFIC LLC
5213 Maple Street, Bellaire, TX77401

Telephone (713) 661-6267

FAX (713) 661-6267

Date Prepared: Jul. 10th, 2011

Device Name Trade or Proprietary Name: **Healgen Series Reagent Strips and Analyzers for Urinalysis**

Common or Usual Name: **Urinalysis Test Strips and Analyzers**

Device Format Healgen 11 Reagent Strips for Urinalysis
Healgen 10 Reagent Strips for Urinalysis
Healgen 4 Reagent Strips for Urinalysis
Healgen 500 Urine Analyzer
Healgen 800 Urine Analyzer

Classification

| Product Code | Class | Panel | C.F.R. Section |
|--------------|----------|--------------------|----------------|
| JIO | CLASS II | HEMATOLOGY | 864.6550 |
| JIL | CLASS II | CLINICAL CHEMISTRY | 862.1340 |
| CDM | CLASS I | CLINICAL CHEMISTRY | 862.1785 |
| JJB | CLASS I | CLINICAL CHEMISTRY | 862.1115 |
| JIN | CLASS I | CLINICAL CHEMISTRY | 862.1435 |
| JIR | CLASS I | CLINICAL CHEMISTRY | 862.1645 |
| JMT | CLASS I | CLINICAL CHEMISTRY | 862.1510 |
| LJX | CLASS I | HEMATOLOGY | 864.7675 |
| CEN | CLASS I | CLINICAL CHEMISTRY | 862.1550 |
| JMA | CLASS I | CLINICAL CHEMISTRY | 862.1095 |
| KQO | CLASS I | CLINICAL CHEMISTRY | 862.2900 |
| JRE | CLASS I | CLINICAL CHEMISTRY | 862.2800 |

Note: Occult blood test and urinary glucose test are the subjects of this submission.

Predicate Device: URISTK H Series Reagent Strips for Urinalysis and Dirui H-50, H-100, or H-500 Urine Analyzer manufactured by Dirui Industrial Co. Ltd (K040703).

Device Description Healgen Series Reagent strips for Urinalysis and urine analyzers are in vitro diagnostic test devices that use reagents for qualitative and semi-quantitative urinalysis.
The device is composed of several color pads aligned on a strip. Each pad is

employed for testing one assay item by visually or instrumentally reading the color change of the pad and comparing with the corresponding blocks on a color chart.

Healgen Series Reagent Strip provides tests for Glucose, Bilirubin, Ketone, Specific Gravity, Blood, pH, Protein, Urobilinogen, Nitrite, Ascorbic Acid and Leukocytes in Urine.

Intended Use/Indications for Use

Healgen Series Reagent Strips for Urinalysis are in vitro diagnostic test devices that use reagents for qualitative and semi-quantitative urinalysis. The strips are for professional use only.

Healgen Series Reagent Strips for Urinalysis are intended for use to detect conditions indicating possible diabetes, metabolic abnormalities, liver diseases, kidney function, and urinary tract infections. Test results can be used along with other diagnostic information to rule out certain disease states and to determine if microscopic analysis is needed.

Test principles

Urobilinogen: this test is based on the Ehrlich reaction in which p-diethylamino benzaldehyde in conjunction with a color enhancer reacts with urobilinogen in a strongly acid medium to produce a pink-red color.

Bilirubin: The direct bilirubin and dichlorobenzene diazonium produce fuchsia azo dyes in a strongly acid medium.

Ketone: The acetoacetate and sodium nitroprusside cause a reaction in the alkaline medium, which produces a violet color.

Blood: Hemoglobin acts as a peroxidase. It can cause peroxidase to release neo-ecotypes oxide [O]. [O] oxidizes the indicator and causes the color change.

Protein: The test is based on the protein-error-of-indicators principle. An ion in the specific pH indicator attracted by cation on the protein molecule makes the indicator further ionized, which changes its color.

Nitrite: Nitrite in the urine and aromatic amino sulphanilamide are diazotized to form a diazonium compound. The diazonium compound reacting with tetrahydro benzo (h) quinolin 3-phenol causes the color change.

Leukocytes: Granulocyte leukocytes in urine contain esterase that catalyzes the hydrolysis of the pyrrole amino acid ester to liberate 3-hydroxy-5-pheny pyrrole. This pyrrole reacting with diazonium forms a purple color.

Glucose: The glucose oxidized by glucose oxidase catalyzes the formation of glucuronic acid and peroxide hydrogen. Peroxide hydrogen releases neo-ecotypes oxide [O] under the function of peroxidase. [O] oxidizes iodide potassium, which causes the color change.

Specific Gravity: Electrolyte (M+X-) in the form of salt in urine reacts with poly methyl vinyl ether and maleic acid (-COOH), which is a weak acid ionic exchanger. The reaction produces hydrogenous ionogen, which reacts with a pH indicator that causes the color change.

pH: This test is based on a double indicator principle that gives a broad range of colors covering the

entire urinary pH range.

Ascorbic Acid: Ascorbic acid, with 1, 2-dihydroxy alkenes, under the alkaline condition, deoxidizes the blue 2, 6-dichloroindophenolate into colorless N- (p-phenol)-2, 6-dichloro-p-amine phenol.

Technological characteristics

Studies were performed with the reference URISTK H Series Reagent Strips for Urinalysis and Urine Analyzer. And substantial equivalence has been demonstrated to the reference method.

Comparison with the predicate:

| Differences and Similarities | | |
|--------------------------------------|--|--|
| Item | New Device | Predicate Device |
| Intended Use | Healgen Series Reagent Strips for Urinalysis are in vitro diagnostic test devices that use reagents for qualitative and semi-quantitative urinalysis. The strips are for professional use only. Healgen Series Reagent Strips for Urinalysis are intended for use to detect conditions indicating possible diabetes, metabolic abnormalities, liver diseases, kidney function, and urinary tract infections. Test results can be used along with other diagnostic information to rule out certain disease states and to determine if microscopic analysis is needed. | This guide instructs the methods, reaction principles and points for attention for the use of URISTK H Series of Reagent Strips. URISTK H Series of Reagent Strips are made for urinalysis both qualitative and semi-quantitative, which are in vitro reagent for diagnostics. The strips are for professional use only. The results on the strips can be read visually and instrumentally. You are required to read the User's Guide before taking use of the strips. |
| Specimen | Fresh urine | The same |
| Methodology | Established clinical chemistry methods | The same |
| Test strip analytes that can be read | Urobilinogen, Billirubin, Ketone, Blood, Protein, Nitrite, Leukocytes, Glucose, Specific Gravity, pH, and Ascorbic Acid | The same |
| Strip Incubation Time | Immerse the reagent area of the strip in the urine specimen and take it up quickly and immediately. | The same |
| Detection | Reflectance Photometry | The same |
| PC Port | Standard RS232C | The same |
| Analyzer Operating Conditions | 0~40°C:RH < 85% | The same |
| Wavelength | 420nm, 525nm, 560nm, 610nm, 660nm, 950nm | The same |
| Calibration | Done with a cilibration strip | The same |
| Strip Operating | Semi-automatic | The same |
| Available Languages on screen | English | The same |
| Power Source | AC 220V(±15%),50~60Hz | The same |
| Line Leakage Current | <0.5 milliamperes in normal condition; <3.5 milliamperes in single fault condition | The same |

| | | |
|--------------------|--|---|
| Memory | 1000 test results | The same |
| Throughput | Healgen 500: 120 test/hour | Dirui-50: 60 test/hour |
| | Healgen 800: 500 test/hour | Dirui-100: 120 test/hour |
| | | Dirui-500: 500 test/hour |
| Dimensions | 355mm×300mm×145mm | 324mm×327mm×185mm |
| Weight | 4kg | About 5kg |
| Display Dimensions | Healgen 500 240mm*64mm Healgen 800 240mm*128mm | Dirui-50: 240mm*64mm Dirui-100: 240mm*64mm Dirui-500: 240mm*128mm |

Performance

The following are performance characteristics of the Healgen Series Reagent Strips for Urinalysis and Healgen Series Urine Analyzers.

a. Analytical limits (cutoff):

We demonstrated the analytical limits of each assay item as below:

| Analyte | Unit | Cutoff |
|------------------|-----------------|--------|
| Urobilinogen | mg/dl | 0.7 |
| Bilirubin | mg/dl | 0.7 |
| Ketone | mg/dl | 3.5 |
| Blood | cells/ μ L | 6.5 |
| Protein | mg/dl | 7.2 |
| Nitrite | μ g/dL | 50 |
| Leukocytes | cells / μ L | 10 |
| Glucose | mg/dl | 65 |
| Ascorbic Acid | mg/dl | 6.5 |
| pH | | 5.6 |
| Specific Gravity | | 1.003 |

b. Precision (repeatability/reproducibility):

Within-run and within-day precisions were determined at 3 clinical sites by 6 technicians.

In within-run precision testing, 20 replicates were run on each of the 3 levels of urine controls. Each of the 20 replicates was assayed consecutively, using strips obtained from each of 3 lots strips.

In within-day precision testing, the 3 levels were analyzed in duplicate, one a day, for 10 days using strips obtained from 3 lots of strips.

All the 3 formats (Healgen 11, 10 and 4) strips and both of the reading method were used to perform the abovementioned evaluation. For instrumental reading, both Healgen 500 and Healgen 800 were used.

Urinalysis control Level 1 and Level 2 of Bio-Rad and a 3rd control with analyte concentrations around cutoff were used as samples for lower and higher levels.

The 3rd control was obtained by pooling the Bio-Rad controls and spiking with certain kinds of pure analytes to make all the analyte concentrations near the cutoff values.

c. Reportable ranges:

Healgen Series Reagent Strips for Urinalysis are qualitative and semi-quantitative. The strips give results in a small range of concentration of each analyte. All the output values of Healgen Series Reagent Strips are within the laboratory assay ranges. The laboratory assay range and the reportable range of Healgen strips for each analyte are listed in the following table:

| Analyte | Unit | Lab Assay Range | Reportable Range |
|------------------|-----------------|-----------------|------------------|
| Urobilinogen | mg/dl | 0.01-18.75 | 0.2-8 |
| Bilirubin | mg/dl | 0-18.8 | 0-6 |
| Ketone | mg/dl | 0.2-350 | 0-160 |
| Blood | cells / μ L | 0-350 | 0-200 |
| Protein | mg/dl | 0.3-5000 | 0-2000 |
| Nitrite | mg/dl | 5.0-2000 | Neg-Pos |
| Leukocytes | cells/ μ L | 0-800 | 0-500 |
| Glucose | mg/dl | 0-5500 | 0-2000 |
| Specific Gravity | | 1.000-1.040 | 1.000-1.030 |
| pH | | 0-14.0 | 5.0-8.5 |
| Ascorbic Acid | mg/dl | 1-230 | 0-100 |

d. Analytical specificity

The interference study was carried out by adding known amounts of potential interfering substances to urine samples and evaluated the test results. 5 test strips from each of 3 lots were used for each interference test, and all the interferents were tested in a one-at-a-time way.

A table of the studied concentrations of the potentially interfering substances that will not have influence on the test results is shown as below:

| Potential Interfering Substance | Concentration Not Affecting Test |
|---------------------------------|----------------------------------|
| Albumin | 800 mg/dL |
| Ascorbic Acid | 50 mg/dL |
| Hemoglobin | 50 mg/dL |
| Citric Acid | 50 mg/dL |
| Bilirubin | 3.0 mg/dL |
| Creatine | 8 mg/dL |
| Acetoacetate Acid | 1 mmol/L |
| Ammonium Chloride | 189 mg/dL |
| Calcium Chloride | 50 mg/dL |
| Creatinine | 800 mg/dL |
| Glucose | 2000 mg/dL |
| Glycine | 1000 mg/dL |
| KCL | 550 mg/dL |
| NaCl | 2800 mg/dL |
| Oxalic Acid | 70 mg/dL |
| Sodium Acetate | 1200 mg/dL |
| Sodium Bicarbonate | 1500 mg/dL |
| Sodium Nitrate | 0.26 mg/dL |
| Sodium Nitrite | 0.3 mg/dL |

| | |
|------------------|-------------------|
| Sodium Phosphate | 16 mg/dL |
| Urobilinogen | 3.0 mg/dL |
| Urea | 3000 mg/dL |
| Riboflavin | 100 mg/L |
| Theophylline | 100 mg/L |
| Phenolphthalein | 1200 mg/L |
| pH | 9.0 |
| Specific gravity | 1.030 |
| Glutathione | 200mg/dL |
| Hypochlorite | 10mg/L |
| Chlorine | 1mg/dL |
| Peroxide | 1mg/L |
| Atropine | 300mg/L |
| Fructose | 5000 mg/dL |
| Lactose | 5000 mg/dL |
| Leucocytes | 800 Cell/ μ L |
| Ketone | 200 mg/dL |
| Blood | 300 Cell/ μ L |
| Mesna | 50mg/dL |

e. Comparison Studies Using Clinical Specimens

The clinical comparison studies were conducted in 3 sites using the Healgen 11 Reagent Strip for Urinalysis and the predicate devices. Data obtained by visually reading and instrumental reading (Healgen 500 and 800) were collected. The study results indicated that comparable testing data could be obtained by intended users when using the Healgen 11 Reagent Strip for Urinalysis and the legally marketed URISTK H Series Reagent Strips for Urinalysis from Dirui.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Healgen Scientific, LLC
c/o Yongquan Wang
Quality Manager
5213 Maple Street
Bellaire, TX 77401

APR 17 2012

Re: k111999
Trade Name: Healgen Series Reagent Strips and Analyzers for Urinalysis
Regulation Number: 21 CFR 864.6550
Regulation Name: Occult blood test
Regulatory Class: Class II
Product Code: JIO, JIL, CDM, JJB, JIN, JIR, JMT, LJX, CEN, JMA, JRE, KQO
Dated: April 6, 2012
Received: April 9, 2012

Dear Mr. Wang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>

Sincerely yours,



Courtney H. Lias, Ph.D.
Director
Division of Chemistry and Toxicology Devices
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and Radiological Health

Enclosure

Indications for Use Form

510(k) Number (if known): K111999

Device Name: Healgen Series Reagent Strips for Urinalysis

Indications for Use:

The Healgen Series Urine Reagent Strips and Urine Analyzers are in-vitro test systems intended for qualitative and semi-quantitative analysis of Urobilinogen, Bilirubin, Ketone, Blood, Protein, Nitrite, Leucocytes, Glucose, Specific gravity, pH and Ascorbic Acid in urine. The test systems consist of the Healgen Series Reagent Strips (Healgen 10 and Healgen 11) and the Healgen 500 or Healgen 800 Urine Analyzers. The Healgen 10 and 11 strips can be read visually and instrumentally with the Healgen 500 and 800 Analyzers. The Healgen 4 reagent strip can be read visually only. The Healgen Series Urine Reagent Strips and Urine Analyzers are intended for use to detect conditions indicating possible diabetes, metabolic abnormalities, liver diseases, kidney function, and urinary tract infections. Test results can be used along with other diagnostic information to rule out certain disease states and to determine if microscopic analysis is needed.

The Healgen 500 and 800 Urine Analyzers use reflectance photometry to quantitate analyte values from urine samples when using the Healgen 10 and 11 reagent test strips."

Prescription Use X AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER
PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)



Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K111999